Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Pharmaceutical composition for preventing or treating cold injury and thrombus

A composition and drug technology, applied in the field of medicine, to achieve the effect of shortening the length of thrombus formation, reducing drug side effects, preventing or treating cold injury

Active Publication Date: 2015-08-19
INST OF HYGIENE & ENVIRONMENTAL MEDICINE PLA ACAD OF MILITARY MEDICAL +1
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] At present, there are no drugs specifically for the prevention and treatment of cold injury in clinical practice. Therefore, it is of great clinical significance to study drugs that can prevent or treat cold injury

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for preventing or treating cold injury and thrombus
  • Pharmaceutical composition for preventing or treating cold injury and thrombus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Example 1 Effects of anisodamine, prazosin and their compositions on the length of tail thrombus in mice induced by carrageenan in cold environment.

[0034] Experimental method: SPF grade male Kunming mice weighing 18-22 g (purchased from the Experimental Animal Center of the Academy of Military Medical Sciences) were given 5 mg.kg of type I carrageenan -1 (0.05% solution prepared with normal saline, intraperitoneally injected at a volume of 0.1ml per 10g of body weight), the mice in the test drug group were given the test drug by intragastric prophylaxis at 0.1ml / 10g body weight 30 minutes before injection of carrageenan (also prepared with normal saline) (concentrations of anisodamine are 0.008%, 0.024%, 0.072%, prazosin concentrations are 0.0007%, 0.002%, 0.006% (concentration unit g / ml) The two drugs were combined and prepared in normal saline. The model group was given normal saline). After injecting carrageenan, the mice were exposed to cold at 18±1°C and 30-50%...

Embodiment 2

[0040] Example 2 The effect of the composition of anisodamine and prazosin on the length of tail thrombus induced by carrageenan in mice under cold environment.

[0041] Experimental model: SPF-grade male Kunming mice weighing 18-22 g were given 2.5 mg.kg of type I carrageenan -1 (0.025% solution prepared with normal saline, injected intraperitoneally at a volume of 0.1ml per 10g of body weight), the mice in the test drug group were given the test drug by intragastric prophylaxis at 0.1ml / 10g body weight 30 minutes before injection of carrageenan (prepared with normal saline) (in each dose group, the concentrations of anisodamine were 0.025%, 0.02%, 0.016%, 0.012%, 0.008%, and the concentrations of prazosin were 0.275%, 0.021%, 0.002%, 0.006% (concentration unit g / ml), the blank control group was intraperitoneally injected and gavaged with the same volume of normal saline, the model group was only given type Ⅰ carrageenan, and no test drug was given, and then the mice were rea...

Embodiment 3

[0048] Example 3 Effects of anisodamine combined with prazosin and tolazoline on blood coagulation and fibrinolysis in mice with carrageenan-induced thrombosis in cold environment.

[0049] The modeling and experimental methods of this example are the same as those of Example 2, and the content of plasma prothrombin time (PT), activated partial thromboplastin time (APTT), and plasma tissue plasminogen activator (t-PA) is detected and plasminogen activator inhibitor-1 (PAI-1) levels. (Use the platelet aggregation coagulation factor analyzer for further operation according to the requirements of the PT and APTT assay kit instructions; for the determination of t-PA and PAI-1 content, follow the requirements of the enzyme-linked immunosorbent assay kit instructions).

[0050] Experimental results: Compared with the blank control group, the PT of the model group was significantly shortened, the plasma t-PA content was significantly reduced, and the PAI-1 content was significantly i...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of a medicine, relates to a pharmaceutical composition for preventing or treating cold injury and thrombus, and particularly relates to use of a pharmaceutical composition including an M cholinoceptor blocking drug and an alpha1 receptor antagonist drug, and use of the pharmaceutical composition for preparing a drug for preventing or treating the cold injury, chimatlon, thrombus or protecting vascular endothelial cells. The invention is confirmed that the cold injury can be effectively prevented or treated by combination of the M cholinoceptor blocking drug and the alpha1 receptor antagonist drug; the thrombus can be effectively reduced; the thrombus forming length is shortened; the pharmaceutical composition has the function of protecting the vascular endothelial cells; the effect is much superior to that of a single drug; and the two drugs have synergistic effects by combination.

Description

technical field [0001] The invention belongs to the technical field of medicine, and relates to a pharmaceutical composition for preventing or treating cold injury, in particular to a pharmaceutical composition comprising an M choline receptor blocking drug and an α1 receptor blocking drug, and for the pharmaceutical composition. The invention is used for preparing medicines for preventing or treating cold injury, frostbite, thrombus, or protecting vascular endothelial cells. Background technique [0002] Cold injury is the injury caused by the cold stimulation of the body, clinically divided into systemic cold injury and localized cold injury. Systemic cold injury includes "hypothermia" (freezing stiffness), and localized cold injury includes freezing injury and non-freezing injury. Freezing injury, referred to as frostbite; non-freezing injury includes frostbite, trench foot, dipping foot, etc., among which frostbite and frostbite are more common. The strength of cold in...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K45/06A61K31/517A61P7/02A61P9/14A61P43/00A61K31/46A61K31/4174
Inventor 汪海宁萌张雁芳杨丹凤石永平
Owner INST OF HYGIENE & ENVIRONMENTAL MEDICINE PLA ACAD OF MILITARY MEDICAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com